Ionis Pharmaceuticals Inc (IONS) Chairman Sells $856,576.24 in Stock

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 16,549 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, January 15th. The stock was sold at an average price of $51.76, for a total value of $856,576.24. Following the completion of the transaction, the chairman now directly owns 67,626 shares of the company’s stock, valued at approximately $3,500,321.76. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) opened at $50.22 on Friday. Ionis Pharmaceuticals Inc has a twelve month low of $37.26 and a twelve month high of $65.51. The company has a market capitalization of $6,201.09, a PE ratio of 331.27 and a beta of 2.86. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21.

IONS has been the subject of several recent analyst reports. BMO Capital Markets reaffirmed an “outperform” rating and issued a $69.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, October 2nd. Goldman Sachs Group reaffirmed a “sell” rating and issued a $30.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, October 6th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $50.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 price target for the company in a research report on Tuesday, October 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $50.76.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IONS. Steward Partners Investment Advisory LLC bought a new stake in Ionis Pharmaceuticals in the 3rd quarter worth about $100,000. Hanseatic Management Services Inc. grew its stake in shares of Ionis Pharmaceuticals by 1.2% during the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after purchasing an additional 41 shares during the period. Parallel Advisors LLC grew its stake in shares of Ionis Pharmaceuticals by 60.3% during the 3rd quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after purchasing an additional 1,250 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Ionis Pharmaceuticals by 9.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares during the period. Finally, WFG Advisors LP grew its stake in shares of Ionis Pharmaceuticals by 77.2% during the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after purchasing an additional 1,655 shares during the period. Institutional investors own 91.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Ionis Pharmaceuticals Inc (IONS) Chairman Sells $856,576.24 in Stock” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/20/ionis-pharmaceuticals-inc-ions-chairman-sells-856576-24-in-stock.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply